These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
847 related articles for article (PubMed ID: 31711920)
21. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506 [TBL] [Abstract][Full Text] [Related]
22. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830 [TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. Yoneda M; Fujiwara H; Furutani A; Ikai A; Tada H; Shiozaki A; Komatsu S; Kubota T; Ichikawa D; Okamoto K; Konishi H; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Otsuji E Anticancer Res; 2013 Jun; 33(6):2699-705. PubMed ID: 23749929 [TBL] [Abstract][Full Text] [Related]
24. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502 [No Abstract] [Full Text] [Related]
25. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894 [TBL] [Abstract][Full Text] [Related]
26. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476 [TBL] [Abstract][Full Text] [Related]
27. Curative treatment for esophageal cancer: Vancouver Island Cancer Centre experience from 1993 to 1998. Wilson KS; Wilson AG; Dewar GJ Can J Gastroenterol; 2002 Jun; 16(6):361-8. PubMed ID: 12096299 [TBL] [Abstract][Full Text] [Related]
28. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637 [TBL] [Abstract][Full Text] [Related]
29. [Esophageal cancer: outcome according to therapeutic strategy]. Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680 [TBL] [Abstract][Full Text] [Related]
30. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. Jun S; Shukla NA; Durm G; Hui AB; Cao S; Ganti AK; Jabbour SK; Kunder C; Alizadeh AA; Hanna NH; Diehn M J Thorac Oncol; 2024 Oct; 19(10):1427-1437. PubMed ID: 38971369 [TBL] [Abstract][Full Text] [Related]
31. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112 [TBL] [Abstract][Full Text] [Related]
32. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314 [TBL] [Abstract][Full Text] [Related]
33. Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal adenocarcinoma. van den Ende T; van der Pol Y; Creemers A; Moldovan N; Boers D; van Berge Henegouwen MI; Hulshof MC; Cillessen SA; van Grieken NC; Pegtel DM; Derks S; Bijlsma MF; Mouliere F; van Laarhoven HW J Pathol; 2023 Nov; 261(3):286-297. PubMed ID: 37615198 [TBL] [Abstract][Full Text] [Related]
34. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884 [TBL] [Abstract][Full Text] [Related]
35. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Barbetta A; Nobel TB; Sihag S; Hsu M; Tan KS; Bains MS; Isbell JM; Janjigian YY; Wu AJ; Bott MJ; Jones DR; Molena D Ann Thorac Surg; 2018 Sep; 106(3):864-871. PubMed ID: 29738752 [TBL] [Abstract][Full Text] [Related]
36. Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma. Zhang D; Zhou X; Bao W; Chen Y; Cheng L; Qiu G; Sheng L; Ji Y; Du X Oncotarget; 2015 Nov; 6(35):38410-20. PubMed ID: 26334098 [TBL] [Abstract][Full Text] [Related]
37. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622 [TBL] [Abstract][Full Text] [Related]
38. Association of post-operative ctDNA detection with outcomes of patients with early breast cancers. Cutts R; Ulrich L; Beaney M; Robert M; Coakley M; Bunce C; Crestani GW; Hrebien S; Kalashnikova E; Wu HT; Dashner S; Sethi H; Aleshin A; Liu M; Ring A; Okines A; Smith IE; Barry P; Turner NC; Garcia-Murillas I ESMO Open; 2024 Sep; 9(9):103687. PubMed ID: 39216186 [TBL] [Abstract][Full Text] [Related]
39. Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study. Boeken T; Pellerin O; Bourreau C; Palle J; Gallois C; Zaanan A; Taieb J; Lahlou W; Di Gaeta A; Al Ahmar M; Guerra X; Dean C; Laurent Puig P; Sapoval M; Pereira H; Blons H Radiol Med; 2024 Oct; 129(10):1530-1542. PubMed ID: 39183242 [TBL] [Abstract][Full Text] [Related]
40. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]